ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
News Source : Financial Post
News Summary
- U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program’s potential for priority review.
- No cases of amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhage, have been observed to date.
- Over 50% enrolled, no cases of ARIA and no patient dropouts to dateStrengthened Financial Position with $21.6 million in Gross Proceeds Raised in July 2025.
Forwardlooking Statements Nasdaq has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forwardlook [+12295 chars]
Never miss a story from us, subscribe to our newsletter